Both Moderna and Pfizer maintained their financial forecasts for COVID-19 vaccine sales this year, estimating product revenue that between them totals more than $50 billion.
Yet the trajectory of those sales has become harder for analysts to predict amid questions about how additional booster doses might be rolled out and whether purchasing in the U.S. might shift from the federal government to private payers.
